secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2022-06-03T23:59:59+00:00
Accession:  0001714899-22-000082
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Therapeutics elects three Class II directors at 2022 annual meeting
--------------------------------------------------------------------------

- Vicki Sato (65.5M for, 15.5M withheld), Erik Harris (80.6M for, 0.3M withheld), and Peter Klein (67.3M for, 13.6M withheld) elected as Class II directors.
- Ratification of Ernst & Young as independent auditor for FY2022 passed with 86.8M for, 16K against, 37K abstain.
- Non-binding advisory vote on executive compensation approved with 75.8M for, 4.5M against, 0.6M abstain.
- 70.70% of outstanding shares (86.9M of 122.9M) represented at the meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489922000082/0001714899-22-000082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489922000082/dnli-20220602.htm
  HTML page:      https://secwatch.observer/filing/0001714899-22-000082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer